All Comparisons
Retatrutide vs Cagrilintide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Retatrutide: BCagrilintide: B
| Attribute | Retatrutide | Cagrilintide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Amylin Analog |
| Evidence Rating | B — Phase III / NDA Filed | B — Phase III / NDA Filed |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase 3 (REDEFINE program). NDA filed with FDA in 2026 for CagriSema. |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal... | Cagrilintide activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other hindbrain regions, promoting meal-related satiety through distinct pathways from GLP-1 agonism. It slows gastric emptying, suppresses inappropriate glucagon release, and activates central ap... |
| Half-Life | ~6 days (allows once-weekly dosing) | ~7 days (allows once-weekly dosing) |
| Bioavailability | SC injection | SC injection |
| Molecular Weight | — | — |
| WADA Status | Not Prohibited | Not Listed |
| Research Half-Life | ~6 days (allows once-weekly dosing) | ~7 days (allows once-weekly dosing) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028. | Not yet FDA-approved. NDA filed by Novo Nordisk in 2026 for CagriSema (cagrilintide + semaglutide) for chronic weight management. FDA review expected 2026-2027. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Retatrutide | Cagrilintide |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 2381089-83-2 | N/A |
| Molecular Formula | C₂₂₅H₃₄₈N₆₀O₆₈S₂ | N/A |
| Available Formats | 20mg, 10mg, 5mg, 30mg | 10mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.